Press Releases and Blog
Blog
Reminder: Conservative Thought Leaders And GOP Lawmakers Oppose Anti-PBM Government Mandates
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals
Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
Press Releases
PCMA Statement on HELP Committee Vote on S. 1339
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the legislative markup on S. 1339, the Pharmacy Benefit Manager
PCMA Announces Lucia Lebens as New Senior Vice President of Federal Affairs and Political Strategy
Named a 2022 Top Lobbyist by The Hill, Lebens Will Lead PCMA’s Federal Lobbying Team (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is
PCMA Launches Ad Campaign on Value of Pharmacy Benefit Companies and Solutions to Lower Prescription Drug Costs
Campaign Highlights How Pharmacy Benefit Companies Work Every Day to Secure Savings, Enable Better Health Outcomes, Support Access to Quality Rx Coverage and Promote Competition
PCMA Statement on Senate Commerce Committee Hearing on Anti-Competitive Legislation
S. 127 Does Nothing to Address Root Cause of High Drug Prices and Would Increase Costs for Patients and Employers (Washington, D.C.) — Pharmaceutical Care
PCMA Applauds the Senate Judiciary Committee’s Approval of Prescription Drug Pricing Legislation to Promote Greater Competition, Lower Prescription Drug Costs
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) Chief Policy and External Affairs Officer Kristin Bass released the following statement on the legislative markup on
Express Scripts President Adam Kautzner Appointed Chair of PCMA Board of Directors
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) announced today that Adam Kautzner, PharmD, president of Express Scripts, has assumed the role of chairman
New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma
In case you missed it, the Brookings Institution released a new analysis, “A Brief Look At Current Debates About Pharmacy Benefit Managers,” which provides an
ICYMI: PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
ICYMI: Pharmacy Benefit Managers Are Not To Blame For Rising Drug Prices
PCMA Urges Congress to Listen to Constituents and Address Rising Drug Prices In case you missed it, JC Scott, president and CEO of the Pharmaceutical
ICYMI: Costello: Targeting Pharmacy Benefits Would Raise Drug Costs
In case you missed it, former U.S. Representative for Pennsylvania’s 6th Congressional District Ryan Costello discusses how recent legislation targeting pharmacy benefit companies will raise
ICYMI: A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Experts Underscore the Root Cause of High Prescription Drug Prices – Big Pharma’s Anti-Competitive Tactics
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that
ICYMI: Pharmacy Benefit Companies Support all Members of the Supply Chain
In case you missed it, Johnny Garcia, PharmD, Senior Director, Policy at the Pharmaceutical Care Management Association (PCMA), explains the critical role pharmacy benefit companies
Experts Weigh In on the Critical Cost Saving Role of Pharmacy Benefit Companies
Health care, business, political, and economic experts all agree pharmacy benefit companies deliver significant savings and play a critical role mitigating costs and supporting access
ICYMI: Economic Experts Sound Alarm On Misguided Legislation Targeting Pharmacy Benefit Companies
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan,
Don’t Be Fooled: Big Pharma Keeps the Vast Majority of the Rx Dollar
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug